Iterum Therapeutics (ITRM)
El Papa mas molón
20-ene-2021 22:46
#1
|
Vengo a daros a conocer Iterum Therapeutics (ITRM) Se avecinan buenos catalizadores entre ellos una fusión y una aprobación de la fda para un producto Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. "Resolution No. 8 sought approval for the acquisition by investment funds managed and controlled by Sarissa Capital Management LP (together the Sarissa Funds) of up to 60% of the total issued ordinary share capital of the Company [. . .]" " Assuming (i) the Sarissa Funds exchange the Sarissa Notes in full at the earliest possible opportunity, being January 21, 2021 [. . .]" 30% subida hoy, cotiza a 1.70 en el momento de escribir esto Volumen: 65.690.019 Nasdaq compliance in 2 days and decision about NDA for sulopenem within 2 weeks. Que cada uno haga su investigación por supuesto, los fundamentales son buenos Yo he comprado en 1.40 hoy, manteniendo los 1.99 que ha alcanzado. En verdes praderas me hace descansar Animo shurs, luego de esto atvk y gthc |
ForoCoches: Miembro
20-ene-2021 23:03
#2
| En su momento estuvo a 12 (hace casi 3 años). De verdad crees que tiene potencial? |
ForoCoches: Miembro
11-feb-2021 17:42
#3
|
Vengo a daros a conocer Iterum Therapeutics (ITRM)
Se avecinan buenos catalizadores entre ellos una fusión y una aprobación de la fda para un producto Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. "Resolution No. 8 sought approval for the acquisition by investment funds managed and controlled by Sarissa Capital Management LP (together the Sarissa Funds) of up to 60% of the total issued ordinary share capital of the Company [. . .]" " Assuming (i) the Sarissa Funds exchange the Sarissa Notes in full at the earliest possible opportunity, being January 21, 2021 [. . .]" 30% subida hoy, cotiza a 1.70 en el momento de escribir esto Volumen: 65.690.019 Nasdaq compliance in 2 days and decision about NDA for sulopenem within 2 weeks. Que cada uno haga su investigación por supuesto, los fundamentales son buenos Yo he comprado en 1.40 hoy, manteniendo los 1.99 que ha alcanzado. En verdes praderas me hace descansar Animo shurs, luego de esto atvk y gthc |
El Papa mas molón
11-feb-2021 22:54
#4
| Que va shurhand, no aguanto casi ninguna yo, estoy pendiente de los earnings de dentro de un rato de sprwf, lo que gane para cbbt, que por cierto, recomiendo |